I. FINANCING OF PRIVATE BIOTECHNOLOGY COMPANIES: $379.7M

Company

Location

Date

Amt. (M)

Details


BioMimetic
Pharmaceuticals
Inc.

Franklin, Tenn.

11/4/04

$25.7

The Series C financing was led by InterWest Partners; other investors included CMEA Ventures, MC Life Science Ventures, Burrill & Co., Novo A/S, Holden Capital and MB Venture Partners; Pacific Growth Equities LLC was place- ment agent

Chimerix Inc.

San Diego

11/4/04

$11

New investor Frazier Healthcare Ventures led the Series C preferred stock round; founding investors Sanderling Ventures and Asset Management Co. also participated

Ellipsis Neuro-
therapeutics
Inc.

Toronto

11/8/04

C$6 (US$5)

The Series A financing was led by Newport Partners and included the Canadian Medical Discoveries Fund; Transition Therapeutics Inc. also participated and gained a 17% stake in Ellipsis, with an option to increase it to 52%

Inpharmatica
plc

London

11/8/04

£13.9
(US$25.7)

The third-round financing was led by Reed Elsevier Ventures and included Abingworth, Advent, Gilde, GIMV and 3i

JDS
Pharmaceuticals
LLC

New York

11/16/04

$62

AIG Healthcare Partners LP and Galen Partners LP led the private financing round

Metabolex
Inc.

Hayward, Calif.

11/20/04

$44

Alta Partners led the third closing of a Series C financing round; it raised $31M more in closings dating to August 2003; other investors included Venrock Associates, Versant Ventures, Novo A/S, Bay City Capital, KBC Bank & Insurance Group, Birchmere Ventures and VantagePoint Venture Partners

Neosil Inc.

South San Francisco

11/8/04

$32

MPM Capital and Burrill & Co. led the Series A preferred stock round

ODC Therapy
Inc.

Dallas

11/1/04

$4

Baylor Health Care System formed the company and provided $4M in seed financing

Procognia Ltd.

Maidenhead, UK

11/8/04

$23.5

Lead investor Apax Partners Funds was joined by existing investors Evergreen Partners and Koor CVC and new investor Star Ventures in the financing round

Reata Discovery Inc.

Dallas

11/11/04

$12

Investing in the Series C financing were Cardinal Investment Co., Ojai Goliad, StarTech Ventures and undisclosed institutions and individuals

Symphogen A/S

Copenhagen, Denmark

11/2/04

$25

Investors in the Series C financing included Essex Woodlands Health Ventures (USA), Scandinavian Life Science Venture, Novo A/S, LD Pensions and Vaekstfonden

Synta
Pharmaceuticals
Corp.

Lexington, Mass.

11/22/04

$80

Existing investors that participated in the Series D financing included Caxton Group, Galleon Group, AIG SunAmerica and Aperture Partners; new institutions and individuals also participated

Transport
Pharmaceuticals
Inc.

Philadelphia

11/22/04

$27

Carlyle Venture Partners and Quaker BioVentures Inc. co-led the Series D round; existing investors, including investors affiliated with The Hillman Co., and new investor EGS HealthCare Capital Partners also participated

Zyentia Ltd.

Cambridge, UK

11/17/04+

£1.5 (US$2.8)

Details on the first-round funding were not disclosed

II. MILESTONE PAYMENTS AND EQUITY INVESTMENTS FROM EXISTING CORPORATE PARTNERS: $21.25M

Company
(Symbol)#*

Partner (Country)

Amt. (M)

Triggering Event

Details (Date)


Abgenix Inc.
(ABGX)

CuraGen Corp.

ND

Milestone payment

Triggered by the advancement of CR002, a fully human antibody against PDGF-D created by Abgenix, into a Phase I trial, the first trial from their collaboration (11/18)

Celgene
Corp.
(CELG)

Novartis Pharma AG (Switzerland)

$7.5

Milestone payment

Triggered by the FDA's acceptance for review Novartis' NDA seeking approval of Focalin XR for treating pediatric and adult attention deficit/hyperactivity disorder (10/25)**

Cell
Therapeutics
Inc.
(CTIC)

Nippon Shinyaku Co. Ltd. (Japan)

$0.5

Milestone payment

Triggered by Nippon getting approval of Trisenox in Japan for treating relapsed or refractory acute promyelocytic leukemia (10/25)**

ChondroGene
Ltd.
(Canada;
TSE:CDG)

Pfizer Inc.

$1

Milestone payment

The third and final milestone was reached in their October 2002 collaboration to identify therapeutic targets and diagnostic biomarkers for osteoarthritis (11/15)

Galapagos
Genomics NV*
(the Netherlands)

Wyeth

ND

Milestone payment

Wyeth selected a set of targets for internal development from their November 2003 collaboration in osteoporosis (11/9)

Genelabs
Technologies
Inc.
(GNLB)

GlaxoSmithKline plc (UK)

$0.75

Milestone payment

Related to trial results for GSK's vaccine against the hepatitis E virus, which it is devel- oping under a license from Genelabs (11/11)

Isis
Pharmaceuticals
Inc.
(ISIS)

Eli Lilly and Co.

$1.5

Milestone payment

Triggered by the move into Phase I trials of the antisense cancer drug LY2181308, which was licensed to Lilly in April 2003 (11/17)

Medarex Inc.
(MEDX)

Amgen Inc.

ND

Milestone payment

Triggered by Amgen's advancement into clinical trials of an antibody developed using Medarex's UltiMAb technology (11/29)

Pharmacopeia
Drug Discovery Inc.
(PCOP)

Schering-Plough Corp.

ND

Milestone payment

Triggered by Schering-Plough's decision to nominate a cancer compound developed in their collaboration for full preclinical evalu-ation (11/30)

Pharmacopeia
Drug Discovery Inc.
(PCOP)

NV Organon (the Netherlands)

ND

Milestone payment

Triggered by Pharmacopeia's delivery of a development candidate under their 2002 research collaboration (11/9)

Vertex
Pharmaceuticals
Inc.
(VRTX)

Novartis AG (Switzerland)

$10

Milestone payment

Triggered by Novartis' selection of a small- molecule protein kinase inhibitor, VX-322, for clinical development for cancer, under their February 2004 amended collaboration (11/10)


Notes:

# Unless otherwise indicated, shares are traded on the Nasdaq exchange.

* = Private company.

** = Item occurred in October but was not included in previous chart.

+ = Denotes the date the item ran in BioWorld International.

Currency conversions are based on exchange rates at the time of the deal.

ND = Not disclosed.

TSE = Toronto Stock Exchange.

No Comments